It is made available under a CC-BY 4.0 International license .

- 1 The VIPR-1 trial (Visualizing Ischemia in the Pancreatic Remnant) Assessing the role of
- 2 intraoperative indocyanine green perfusion of the transected pancreas in predicting postoperative
- 3 pancreatic leaks: protocol for a phase II clinical trial.
- 4
- 5 Gustavo Salgado-Garza<sup>1</sup>, Annika Willy<sup>1</sup>, Flavio G. Rocha<sup>1, 2, 3</sup>, Skye C. Mayo<sup>1, 2, 3</sup>, Brett C.
- 6 Sheppard <sup>1, 2, 3</sup>, Patrick J. Worth <sup>1, 2, 3, \*</sup>
- 7 <sup>1</sup>Oregon Health & Science University, Department of Surgery, Portland, OR, USA.
- 8 <sup>2</sup> Brenden Colson Center for Pancreatic Care, Oregon Health & Science University, Portland,
- 9 OR, USA.
- 10 <sup>3</sup> Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
- 11 \* Corresponding author
- 12 E-mail: worth@ohsu.edu
- 13 Funding: This study is supported by a Medical Research Foundation of Oregon grant. The
- 14 funders did not participate in the study design and will not be involved in data collection,
- 15 analysis, or dissemination of results.
- 16 Competing interests: The authors have declared that no competing interest exists.
- Data availability: Once the study is completed, relevant, deidentified data from this study will beavailable upon request.
- 19
- 20

It is made available under a CC-BY 4.0 International license .

## 21 Abstract

Surgery of the pancreas has come a long way since its inception; however, postoperative 22 23 morbidity is still high. Pancreatic leaks and fistulas are common complications in patients 24 undergoing surgery to remove the pancreas. Fistulas delay subsequent oncological care after 25 surgery and prolong the hospital stay. Hypoperfusion to the pancreas has been characterized as one factor leading to fistulas. Indocyanine green (ICG) injection allows the surgeon to evaluate 26 27 blood perfusion to tissue in real-time. This protocol describes a trial that aims to assess the 28 effectiveness of intraoperative ICG metrics of the cut edge of the pancreas to predict 29 postoperative fistulas. A single group will participate in an observational, surgeon-blinded, phase 30 II trial. ICG measurements of the cut edge of the pancreas will be recorded before reconstruction. 31 International Study Group on Pancreatic Surgery criteria for pancreatic fistula will be used to 32 define leaks and fistulas. The primary outcome will be the correlation between ICG 33 measurements and the development or absence of fistula formation. Currently, limited objective 34 intraoperative predictors exist for predicting postoperative fistulas. Having a reliable predictive 35 tool could decrease the healthcare burden posed by fistulas. The findings of this trial will provide conclusions on the usefulness of ICG measurements in predicting postoperative pancreatic 36 37 fistulas and leaks. This clinical trial is registered in ClinicalTrials.gov with the ID 38 NCT06084013. The current protocol version is v1.0.

# 39 Introduction

Pancreatic cancer is a deadly disease with a growing incidence rate, causing over 50,000 deaths
annually in the United States [1]. The 5-year survival rate for this cancer is very low, but it can
increase to over 30% with successful surgical resection [2]. However, one of the most serious

It is made available under a CC-BY 4.0 International license .

43 complications of pancreatic surgery is the development of postoperative pancreatic fistulas 44 (POPF) or leaks, which can occur in up to 1 in 3 patients [3]. The impact of POPF on patients is twofold; it not only increases immediate postoperative complications but also adversely affects 45 46 medium to long-term oncological outcomes. POPF increases postoperative mortality because of 47 prolonged hospital stays and higher reoperation rates [4]. In addition, POPF is also linked to 48 worse oncological outcomes for patients, notably tumor recurrence and overall survival [5,6]. 49 Current fistula risk prediction models do not include modifiable intraoperative risk factors for 50 mitigating pancreatic fistula [7]. The poorly perfused surgical neck of the pancreas, vulnerable to 51 ischemia, is a known key factor in developing leaks [8,9]. Indocyanine green (ICG) fluorescence is used to assess tissue perfusion during surgery, but its effectiveness in predicting pancreatic 52 53 leaks has yet to be systematically studied. A reliable intraoperative method to analyze blood 54 perfusion could help guide surgical margins and reduce the risk of pancreaticojejunostomy leaks, ultimately improving patient outcomes. 55 56 Indocyanine green (ICG) is an FDA-approved dye that emits fluorescence when near-infrared 57 light is applied, making it useful for visualizing tissue perfusion during surgery. ICG is injected

58 intravenously, traveling to tissues via arteries. While ICG is now considered standard in some

59 surgical disciplines, it currently needs to be widely used in pancreatic surgery, primarily due to a

60 lack of adequately powered prospective studies analyzing the benefits of its use and surgeons

61 wanting more evidence to change their practices [10]. Regarding pancreatic surgery, ICG is

62 mostly used for anatomical identification of structures to improve surgical safety, avoid damage

63 to critical structures, and delineate tumors for excision [11–13].

In pancreatic surgery, ICG has been used to visualize tissue blood perfusion, with recent studiesshowing promising results [13,14]. Pancreatic surgeons have shown interest in further studies on

It is made available under a CC-BY 4.0 International license .

66	ICG for better visualization of tissue perfusion. A recently published Delphi consensus study
67	reported that almost 80% of experts agreed on the need to focus research efforts of ICG in
68	predicting the risk for POPF [10]. Although research on ICG for evaluating leaks after
69	pancreatectomy is limited, one study showed its potential for detecting leaks in a single patient
70	retrospectively [13]. ICG has shown potential benefits in improving visualization and outcomes
71	in pancreas surgery. Moreover, ICG has an excellent safety profile, with Clavien-Dindo grade $\geq 4$
72	complications occurring in only 0.05% of cases where it is utilized [15]. Long-term potential
73	benefits include correlating ICG uptake with pancreatic remnant perfusion and providing critical
74	information for clinical decisions to avoid POPFs.
75	This study protocol aims to investigate the relationship between hypoperfusion during surgery
76	and the development of postoperative leaks to identify modifiable intraoperative interventions to
77	decrease leak rates. The goal is to leverage the potential positive outcomes from this study to
78	design a phase III clinical trial to evaluate improving remnant gland perfusion and potentially
79	decreasing complications.

# **80 Materials and methods**

This protocol is for a Phase II, open-label, surgeon-blinded, observational study to assess the predictive potential of intraoperative perfusion parameters at the pancreatic cut edge via ICG and its relation to fistula formation versus conventional measurements. The study design consists of a single-arm intervention group at a single academic center: the Oregon Health & Science University Hospital in the United States. Following international and national definitions, this center is considered a high-volume hospital for pancreatectomies [16,17].

It is made available under a CC-BY 4.0 International license .

This study protocol adheres to the SPIRIT guidelines for trial reporting [18]. To ensure adequate
representation of ethnic and racial group demographics in the study, a full consent form and
protocol will be available for English- and Spanish-speaking participants. Short summaries of the
consent forms are available in other languages. Consent will be obtained by members of the
surgical department, including clinical staff and research assistants. This clinical trial is
registered in ClinicalTrials.gov with the ID NCT06084013.

## 93 Sample size

94 Given the limited data of ICG perfusion in the pancreas, the sample size calculation was based 95 on determining a detectable difference between the fistula and no fistula groups. Anticipating 96 balanced numbers between the two groups, our sample size of 50 participants will have 80% 97 power to detect at least a 25% difference in a leak or fistula rate, assuming a 20% leak rate for a 98 normal ICG perfusion group. We account for a liberal exclusion of 30% of participants due to 99 multiple and complex postoperative factors known to be associated with leaks. Therefore, we 910 anticipate screening 75 participants and enrolling 50.

## 101 Eligibility Criteria

102 All participants must fulfill eligibility criteria and have none of the excluding criteria.

- 103 Inclusion Criteria:
- 104 1. Participant scheduled for pancreaticoduodenectomy for any diagnosis.
- 105 2. Participants  $\geq$  18 years of age.
- 106 3. Ability to understand the nature and individual consequences of clinical trials.
- 107 4. Written informed consent from the participant or legally authorized representative.

It is made available under a CC-BY 4.0 International license .

108	5.	For participants of childbearing potential, a negative pregnancy test and adequate						
109		contraception until 14 days after the trial intervention.						
110	6.	Participant needs to have an operative drain (any closed suction drain) after the						
111		procedure.						
112	7.	Participants that do not require arterial reconstruction.						
113	8.	Participants that require minor portal venous reconstruction including patch venoplasty.						
114	Exclusion Criteria:							
115	1.	Patients with previous history of adverse reaction to contrast dye, ICG or components of						
116		the dye.						
117	2.	Prior pancreatectomy.						
118	3.	Known diagnosis of hepatic insufficiency, hepatitis, liver fibrosis or cirrhosis, or chronic						
119		pancreatitis.						
120	4.	Because this study focuses on hypoperfusion, patients will be excluded if in postoperative						
121		day 3-5 had any of the following: persistent SBP <90 mmHg unresponsive to 1L						
122		crystalloid, unexpected ICU transfer, blood transfusion of >2 units intraoperatively or 1						
123		postoperatively, continuous vasopressor treatment or ACLS protocol initiation.						
124	5.	Organ failure, anuria or NSQIP-identified complication will be reviewed by PI and						
125		attending surgeon and decide exclusion.						
126	6.	Patients that require arterial reconstruction as part of their procedures.						

## 127 Blinding

128 To avoid the influence of ICG measurements on surgical decisions at this stage of the trial, this

129 study will involve surgeon-blinding. During intraoperative measurements, the primary surgeon

It is made available under a CC-BY 4.0 International license .

130 must either step outside the operating room or be positioned to avoid a line of sight to the 131 imaging device monitor. The secondary surgeon will remain scrubbed in for this portion of the 132 case. Both study personnel and operating room staff will ensure this blinding process is 133 successful. Any instances of the surgeon viewing the measurements will result in the 134 participant's removal from the study. To ensure adequate surgeon-blinding, objective 135 measurements of the captured images are performed postoperatively, with no relay of this 136 information to the surgeons during the 30 days of the active study phase. Since this study is 137 open-label, participants will know if they received the dye and underwent intraoperative 138 measurements. As this intervention is not standard of care, there is no need for premature 139 unblinding to the surgeons. Imaging measurements will only be available to surgeons and 140 participants after the end of the study follow-up, which is 30 days after surgery.

## 141 Intervention

142 During pancreatectomy, after the surgical specimen is removed and before creating the 143 pancreatojejunostomy anastomosis, a single dose of 12.5 mg (5mL once reconstituted) of ICG 144 will be administered intravenously by the anesthesiologist or certified nurse anesthetist. Spy+ 145 Elite (Stryker, USA) will be used to record perfusion metrics, taking as reference the gastric 146 body and small intestine to compare differences in perfusion of the pancreatic stump. Recording 147 of a video image starts as soon as the dye is injected. Still pictures will be extracted from the 148 video at 10-second intervals once tissue saturation is stable, allowing a comparison of perfusion 149 to the pancreatic stump and the reference tissue.

While measurements and recording of perfusion are being obtained, the primary surgeon will step out of the operating room to ensure that ICG-derived data does not influence the surgical

It is made available under a CC-BY 4.0 International license .

- 152 plan. Upon the study's completion, descriptive statistics will be reported to analyze the impact of
- 153 ICG use and perfusion measurements on pancreatic surgeries. During ICG administration, vital
- signs will be continuously monitored, and hypersensitivity symptoms will be managed promptly.
- 155 An intra-abdominal drainage tube will be placed to assess for amylase levels.
- 156 Participants can withdraw consent at any time. Adverse effects from the study interventions will
- 157 be monitored and reported to institutional authorities. Figure 1 shows the schedule for

158 participants.

- **Figure 1.** SPIRIT Schedule of Enrollment Interventions and Assessments
- 160

## 161 Outcomes

#### 162 Intraoperative

- 163 During the surgery, a 90-120-second video will be captured to analyze ICG perfusion metrics.
- 164 Because no current gold-standard metric exists for this imaging technique in the pancreas,
- several metrics will be analyzed. Quantitative ICG metrics will include absolute and relative ROI
- 166 scores within the Cinevaq (Stryker, USA) software, T0 (the time from ICG injection until the
- 167 first fluorescent signal), TMax (time from the first ICG signal until maximum uptake is
- achieved), as well as ingress and egress rates for the contrast [19,20].

#### 169 **Postoperative**

- 170 After the surgery, the participant would enter the study's follow-up period. The main outcome
- 171 will be the development or absence of postoperative pancreatic fistula, as defined by the most
- updated definition of the International Study Group in Pancreatic Surgery (ISGPS) [21].

It is made available under a CC-BY 4.0 International license .

173 Following this, we will collect surgical drain amylase levels in the first three days after surgery,

174 clinical conditions of the participant, imaging results, and persistent drainage from the drain,

among other factors delineated in the ISGPS. Figure 2 depicts a flowchart for individual

176 participants in the trial.

177 Figure 2. Trial Flowchart. Flowchart for participants in the VIPR-1 trial.

178 Descriptive statistics will be used to compare patients that developed postoperative fistula. ICG

179 metrics will then be compared with multivariable modeling to study the impact they might have

180 on postoperative fistulas.

181 Because there are characteristics that might influence development of POPF, the following

182 participant and case characteristics will be recorded and analyzed as covariates affecting

183 outcomes: 1) type of pancreatectomy, 2) principal surgeon, 3) operative length, 4) blood loss in

184 mL, 5) intraoperative blood transfusion, 6) duct size in mm, 7) gland texture, 8) intraoperative

use of vasopressors, 9) race, 10) BMI, 11) age, 12) neoadjuvant therapy and 13) vascular

186 reconstruction [22].

#### 187 Data management

Data to be collected includes baseline participant demographics relevant to our study, including
sex, age, ethnicity, race, height, weight, ECOG performance status, disease stage at study entry,
cancer therapy and biomarker status.

Collected data will be stored in a trial-specific database that lives in an encrypted cloud service
that is institutionally compliant. Here, participant-level information will be captured without any
of the 18 HIPPA identifiers; a participant key will be stored separately and securely. This study

It is made available under a CC-BY 4.0 International license .

194 will comply with the Data and Safety Monitoring Plan established by the Knight Clinical

195 Research Quality & Administration.

## **196** Safety considerations

- 197 There are two relevant safety considerations for this study. The first involves safety during the
- 198 imaging procedure, and the second involves securing participant data. ICG is considered a
- 199 relatively inert contrast agent compared to other more commonly used imaging agents. The most
- 200 frequently encountered adverse effects of ICG injection include allergic-type reactions,
- 201 presenting as nausea and urticaria, with life-threatening complications such as anaphylactic
- shock being rare (<0.05%) [23]. Participants are made aware of the potential consequences of
- 203 ICG injection at the time of screening and consent.

All adverse effects are reported within 24 hours through the Clinical Trials Management System, connected to ClinicalTrials.gov. The Knight Cancer Institute, as the trial sponsors, performs constant auditing on a participant-level basis. Participant information will be kept secure by restricting access to direct study personnel, and all images and captured participant-level data will be kept in encrypted platforms.

## 209 Ethical considerations

210 The VIPR-1 trial follows guidelines set out by the Declaration of Helsinki [24]. The trial

211 underwent review and subsequent approval from the Knight Cancer Research Institute via the

212 Clinical Research and Review Committee on 9/2023 and then the Institutional Review Board

from Oregon Health and Science University on 11/2023.

## 214 Status and timeline

It is made available under a CC-BY 4.0 International license .

The VIPR-1 trial is registered in the ClinicalTrials government platform [25]. Participant recruitment started on 06/10/2024, and the estimated finishing time is one year after the first patient enrollment. Any updates to the protocol will be informed in the trial registry platform and the protocol itself. After the trial is completed, we intend to publish our results in a scientific journal.

# 220 **Discussion**

221 This is the first prospective clinical trial in the United States to evaluate pancreatic remnant 222 perfusion using ICG to predict fistulas and leaks. A recently published systematic review 223 compiled all reports of the use of pancreatic remnant perfusion intraoperatively. A total of 5 224 studies were found, and only two were prospective [26]. The first prospective trial used ICG for 225 postoperative acute pancreatitis rather than POPF as a primary outcome measure, where 226 adequate statistical power for POPF was not mentioned [14]. The other prospective trial looked 227 at subjective descriptions of adequate blood flow to the pancreatic remnant to characterize 228 hypoperfusion and guide margins [27]. Thus, further highlighting the need for prospective 229 intraoperative and subjective evaluation of perfusion. While studies have reported that 230 hypoperfusion detected by ICG is correlated with POPF, currently, no cutoff for considering 231 adequate or inadequate perfusion exists. After operative measurements are performed, we intend 232 to utilize the Cinevag software (Stryker, USA) to measure the perfusion difference with 233 reference to gastrointestinal tissue and within the pancreas. If a correlation between perfusion 234 and leaks is detected, we will perform statistical analysis at different thresholds for poor 235 perfusion to identify the best cutoff delta in perfusion to predict POPF. A recent study 236 demonstrated that cutoff values for hypoperfusion in breast tissue do not translate between

It is made available under a CC-BY 4.0 International license .

237 different imaging systems. Specifically, a 33% relative perfusion measurement has been

validated in breast tissue, specifically in the SPY-Elite® platform. However, on the newer SPY-

239 PHI platform, the same cutoff value did not correlate with hypoperfusion [28]. While studies like

this are not available in pancreatic tissue, it is possible that a specific cutoff would need to be

241 validated for each type of device model in pancreatic perfusion dynamics.

242 If the results are positive, a phase III study can be designed to evaluate whether ICG metrics can guide surgical margins to optimize perfusion of the pancreatic remnant and decrease POPF. The 243 244 level of the transection of the neck of the pancreas has been previously characterized as 245 important for POPF risk [29]. Capturing patient preoperative and intraoperative variables is 246 crucial to adjust for possible confounders in perfusion observations and the development of 247 POPF. All patients undergoing open pancreatectomy for any diagnosis will be screened for this 248 study. Broad inclusion and exclusion criteria will be implemented to ensure a diverse group of 249 patients and reach the sample size needed.

250 In the past decade, minimally invasive pancreatectomy has gained major interest, as evidenced 251 by numerous studies examining ways to reduce postoperative complications. Current data are 252 inconclusive regarding the impact of surgical technique (open versus minimally invasive) on 253 POPF rates, with some studies suggesting benefits. In contrast, others indicate an increased risk 254 of this outcome with minimally invasive surgery [16,30]. A recent proof of concept prospective 255 study investigated the predictive potential of ICG in determining suture tension-induced 256 hypoperfusion in pancreatic reconstruction. In this study, hypoperfusion to the pancreas by ICG 257 was more frequently encountered in those patients who developed fistulas [31]. This study, however, was performed only in robotic cases, and all measurements were taken after the 258

It is made available under a CC-BY 4.0 International license .

surgeon placed sutures for the anastomosis. We intend to measure perfusion before the pancreasis sutured to the jejunum to measure the complete surface of the remnant to be anastomosed.

261 Pancreatectomies are among the most challenging and lengthy procedures in gastrointestinal

surgery. Because of this, the trial's impact on time added to the case should be minimal.

263 Increases in operative time elevate costs and staff utilization and are associated with surgical

complications in pancreatic surgery [32]. To address this, the operative time will be compared to

control cases that did not undergo ICG measurements. This comparison will determine the

266 impact of ICG measurements on total operative time. Studies in other gastrointestinal surgeries

using ICG have shown a potential increase in operative time by 10-15 minutes, but this increase

has not been statistically significant [33]. We currently do not know the impact of ICG in open

269 pancreatectomies. ICG is now standard in many gastrointestinal procedures but not for the

270 pancreas. We intend to record and subsequently report the effect of ICG on operative time for

271 pancreatectomies.

The main limitation of this study is that our findings might not be generalizable to other
institutions because of inherent differences in practice standards, surgeon experience, and
imaging devices used.

In conclusion, POPF is highly prevalent in pancreatectomy. Current predictive measures to
detect POPF intraoperatively have not been successful in decreasing complication rates. ICG
perfusion of the pancreatic edge could potentially allow surgeons to predict POPF. We aim to
investigate this further with the VIPR-1 trial.

279

# **Authors Contributions - CRediT author statement**

It is made available under a CC-BY 4.0 International license .

- 281 GSG: Writing- Original Draft Preparation, Methodology. AW: Writing- Original draft
- 282 preparation, FGR: Writing- Reviewing and Editing, SCM: Visualization, Writing- Reviewing
- and Editing, BCS: Visualization, Writing- Reviewing and Editing, PJW: Conceptualization,
- 284 Methodology, Writing Original draft, Funding Acquisition, Project Administration.

# 285 Acknowledgments

286 None.

# 287 Supporting information

288 S1 Fig. SPIRIT Checklist.

# 289 **References**

- Cancer Facts & Figures 2023 [Internet]. [cited 2024 Apr 9]. Available from:
   https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2023-cancer facts-figures.html
- Strobel O, Lorenz P, Hinz U, Gaida M, König AK, Hank T, et al. Actual Five-year
   Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma: Who Beats the Odds?
   Ann Surg. 2022 May 1;275(5):962–71.
- 3. Malgras B, Dokmak S, Aussilhou B, Pocard M, Sauvanet A. Management of
  postoperative pancreatic fistula after pancreaticoduodenectomy. J Visc Surg. 2023 Feb
  1;160(1):39–51.
- 4. Torres OJM, Moraes-Junior JMA, Fernandes EDSM, Hackert T. Surgical Management of
  Postoperative Grade C Pancreatic Fistula following Pancreatoduodenectomy. Visc Med.
  2022;38(4):233–42.
- 302 5. Dhayat SA, Tamim ANJ, Jacob M, Ebeling G, Kerschke L, Kabar I, et al. Postoperative
  303 pancreatic fistula affects recurrence-free survival of pancreatic cancer patients. Chen RJ, editor.
  304 PLOS ONE. 2021 Jun 4;16(6):e0252727.
- Bonaroti JW, Zenati MS, Al-abbas AI, Rieser CJ, Zureikat AH, Hogg ME, et al. Impact
  of postoperative pancreatic fistula on long-term oncologic outcomes after pancreatic resection.
  HPB. 2021 Aug;23(8):1269–76.

It is made available under a CC-BY 4.0 International license .

Callery MP, Pratt WB, Kent TS, Chaikof EL, Vollmer CM. A Prospectively Validated
Clinical Risk Score Accurately Predicts Pancreatic Fistula after Pancreatoduodenectomy. J Am
Coll Surg. 2013 Jan;216(1):1–14.

8. Nahm CB, Brown KM, Townend PJ, Colvin E, Howell VM, Gill AJ, et al. Acinar cell
density at the pancreatic resection margin is associated with post-pancreatectomy pancreatitis
and the development of postoperative pancreatic fistula. HPB. 2018 May;20(5):432–40.

Nahm CB, Connor SJ, Samra JS, Mittal A. Postoperative pancreatic fistula: a review of
traditional and emerging concepts. Clin Exp Gastroenterol. 2018 Mar 15;11:105–18.

316 10. De Muynck LDAN, White KP, Alseidi A, Bannone E, Boni L, Bouvet M, et al.

Consensus Statement on the Use of Near-Infrared Fluorescence Imaging during Pancreatic
Cancer Surgery Based on a Delphi Study: Surgeons' Perspectives on Current Use and Future
Recommendations. Cancers. 2023 Jan 20;15(3):652.

11. Newton AD, Predina JD, Shin MH, Frenzel-Sulyok LG, Vollmer CM, Drebin JA, et al.
Intraoperative Near-infrared Imaging Can Identify Neoplasms and Aid in Real-time Margin
Assessment During Pancreatic Resection. Ann Surg. 2019 Jul;270(1):12–20.

323 12. Asbun D, Kunzler F, Marin R, Asbun HJ. Pancreatic fluorescence using continuous
324 indocyanine green infusion. J Surg Oncol. 2022 Dec;126(7):1215–8.

Rho SY, Kim SH, Kang CM, Lee WJ. Is ICG-enhanced image able to help predicting
pancreatic fistula in laparoscopic pancreaticoduodenectomy? Minim Invasive Ther Allied
Technol MITAT Off J Soc Minim Invasive Ther. 2019 Feb;28(1):29–32.

328 14. Doussot A, Decrock M, Calame P, Georges P, Turco C, Lakkis Z, et al. Fluorescence329 based pancreas stump perfusion is associated with postoperative acute pancreatitis after
330 pancreatoduodenectomy a prospective cohort study. Pancreatol Off J Int Assoc Pancreatol IAP
331 Al. 2021 May 18;S1424-3903(21)00161-7.

Hope-Ross M, Yannuzzi LA, Gragoudas ES, Guyer DR, Slakter JS, Sorenson JA, et al.
Adverse Reactions due to Indocyanine Green. Ophthalmology. 1994 Mar;101(3):529–33.

Banni RZ, Panni UY, Liu J, Williams GA, Fields RC, Sanford DE, et al. Re-defining a
high volume center for pancreaticoduodenectomy. HPB. 2021 May;23(5):733–8.

17. El Amrani M, Clément G, Lenne X, Laueriere C, Turpin A, Theis D, et al. Should all
pancreatic surgery be centralized regardless of patients' comorbidity? HPB. 2020
Jul;22(7):1057–66.

18. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al.
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Ann Intern Med.
2013 Feb 5;158(3):200.

342 19. Oppermann C, Dohrn N, Pardes HY, Klein MF, Eriksen T, Gögenur I. Real time organ
343 hypoperfusion detection using Indocyanine Green in a piglet model. Surg Endosc [Internet].

It is made available under a CC-BY 4.0 International license .

344 2024 Jun 13 [cited 2024 Jul 15]; Available from: https://link.springer.com/10.1007/s00464-024 345 10938-0

346 20. Iwamoto H, Matsuda K, Hayami S, Tamura K, Mitani Y, Mizumoto Y, et al. Quantitative
347 Indocyanine Green Fluorescence Imaging Used to Predict Anastomotic Leakage Focused on
348 Rectal Stump During Laparoscopic Anterior Resection. J Laparoendosc Adv Surg Tech. 2020
349 May 1;30(5):542–6.

Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016
update of the International Study Group (ISGPS) definition and grading of postoperative
pancreatic fistula: 11 Years After. Surgery. 2017 Mar;161(3):584–91.

Schuh F, Mihaljevic AL, Probst P, Trudeau MT, Müller PC, Marchegiani G, et al. A
Simple Classification of Pancreatic Duct Size and Texture Predicts Postoperative Pancreatic
Fistula: A classification of the International Study Group of Pancreatic Surgery. Ann Surg. 2023
Mar;277(3):e597.

357 23. Obana A, Miki T, Hayashi K, Takeda M, Kawamura A, Mutoh T, et al. Survey of
358 Complications of Indocyanine Green Angiography in Japan. Am J Ophthalmol. 1994
359 Dec;118(6):749–53.

World Medical Association Declaration of Helsinki: Ethical Principles for Medical
Research Involving Human Subjects. JAMA. 2013 Nov 27;310(20):2191.

362 25. Worth PJ. Assessing the Role of Intraoperative Indocyanine Green Perfusion of the
363 Transected Pancreas in Predicting Postoperative Pancreatic Leaks [Internet]. clinicaltrials.gov;
364 2024 Mar [cited 2023 Dec 31]. Report No.: NCT06084013. Available from:
265 https://clinicaltrials.gov/ctudu/NCT06084013

365 https://clinicaltrials.gov/study/NCT06084013

366 26. Robertson FP, Spiers HVM, Lim WB, Loveday B, Roberts K, Pandanaboyana S.
367 Intraoperative pancreas stump perfusion assessment during pancreaticoduodenectomy: A
368 systematic scoping review. World J Gastrointest Surg. 2023 Aug 27;15(8):1799–807.

369 27. Strasberg SM, Drebin JA, Mokadam NA, Green DW, Jones KL, Ehlers JP, et al.
370 Prospective Trial of a Blood Supply-Based Technique of Pancreaticojejunostomy: Effect on
371 Anastomotic Failure in the Whipple Procedure1. J Am Coll Surg. 2002 Jun;194(6):746–58.

28. Lauritzen E, Bredgaard R, Bonde C, Jensen LT, Damsgaard TE. An observational study
comparing the SPY-Elite® vs. the SPY-PHI QP system in breast reconstructive surgery. Ann
Breast Surg. 2023 Jun;7:12–12.

375 29. Bardol T, Delicque J, Hermida M, Herrero A, Guiu B, Fabre JM, et al. Neck transection
376 level and postoperative pancreatic fistula after pancreaticoduodenectomy: A retrospective cohort
377 study of 195 patients. Int J Surg. 2020 Oct;82:43–50.

378 30. Uijterwijk BA, Kasai M, Lemmers DHL, Chinnusamy P, Van Hilst J, Ielpo B, et al. The
379 clinical implication of minimally invasive versus open pancreatoduodenectomy for non-

pancreatic periampullary cancer: a systematic review and individual patient data meta-analysis.
Langenbecks Arch Surg. 2023 Aug 15;408(1):311.

382 31. Chen JW, Lof S, Zwart MJW, Busch OR, Daams F, Festen S, et al. Intraoperative

383 Fluorescence Imaging During Robotic Pancreatoduodenectomy to Detect Suture-Induced

384 Hypoperfusion of the Pancreatic Stump as a Predictor of Postoperative Pancreatic Fistula

385 (FLUOPAN): Prospective Proof-of-concept Study. Ann Surg Open. 2023 Dec;4(4):e354.

386 32. Williams MD, Bhama AR, Naffouje S, Kamarajah SK, Becerra AZ, Zhang Y, et al.

387 Effect of Operative Time on Outcomes of Minimally Invasive Versus Open

388 Pancreatoduodenectomy. J Gastrointest Surg. 2023 Jan;27(1):93–104.

389 33. Cassinotti E, Al-Taher M, Antoniou SA, Arezzo A, Baldari L, Boni L, et al. European

390 Association for Endoscopic Surgery (EAES) consensus on Indocyanine Green (ICG)

fluorescence-guided surgery. Surg Endosc. 2023 Mar;37(3):1629–48.

392

	STUDY PERIOD					
	Screening	Post-intervention (days)				End of follow up
TIMEPOINT (days)	-1	0	<b>D</b> 1	<b>D</b> <sub>2-7</sub>	<b>D</b> 7-29	<b>D</b> 30
ENROLLMENT:	Х					
Eligibility screen	Х					
medRxiv preprint doi: https://doi.org/10.1101/20 preprint (which was not certified by peer review Informed consent	24.09.13.24313603; this version posted is the author/funder, who has granted n available under a C-BY 4.0 Internation	September 14, 2024. redRxiv a license to c al license .	The copyright holder for this display the preprint in perpet	uity.		
INTERVENTIONS:						
Routine Pancreatectomy			x			
Intraoperative imaging			x			
ASSESSMENTS:						
Health status, medical history, allergies		x				
Tumor size, pathology results		х			х	
Drain amylase				Х		
Signs and symptoms for fistula			x	Х	х	
Postoperative imaging if fistula suspicion			х	Х	Х	
Primary outcome final assessment						Х

Figure 1



# Figure 2